Prescribing guide
Zilbrysq (zilucoplan)REMS, meningococcal vaccination, weight-based dosing, monitoring and prior authorization criteria for gMGFor prescribers and their offices treating generalized myasthenia gravis: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
REMS-certified prescriber; meningococcal ACWY and B vaccination at least 2 weeks before day 1, or antibacterial prophylaxis with vaccines as soon as possible; baseline lipase and amylase; counseling with the Patient Guide and Safety Card; dispensing only through PANTHERx Rare after it documents vaccination status with the office.
Example PA threshold
Cigna example: age 18 or older, anti-AChR positive, MGFA II to IV, MG-ADL 6 or higher, pyridostigmine, 2 immunosuppressants for 1 year or failed, unresolved symptoms, neurologist, no concurrent complement inhibitor, FcRn blocker, rituximab or Uplizna.
Monitoring
Baseline lipase and amylase; meningococcal and other encapsulated bacterial infection at any time; persistent abdominal pain for pancreatitis; revaccination per ACIP for as long as treatment lasts; no repeating lab schedule in the label.
Support line
UCB ONWARD, 1-844-669-2731 (1-844-ONWARD1), Monday to Friday 8 AM to 8 PM ET, Care Coordinator, copay to $0 for commercial plans, PAP up to 12 months; PANTHERx Rare 833-418-7760; REMS 1-877-414-8353.
Give your patient their plan
A one-page handout for starting Zilbrysq, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/zilbrysqBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Certify in the ZILBRYSQ REMS | Review the Prescribing Information, Healthcare Provider Safety Brochure, Patient Safety Card and Patient Guide, then submit the Prescriber Enrollment Form online at ZILBRYSQREMS.com, by email to ZILBRYSQREMS@ppd.com or by fax to 1-877-411-3609. | REMS enrollment form |
| Assess and vaccinate | Exclude unresolved serious N. meningitidis infection, which contraindicates initiation. Complete or update MenACWY and MenB at least 2 weeks before the first dose per ACIP for complement inhibitor recipients; ACIP's schedule differs from the vaccine labels. Prior vaccination may need updating. | FDA label |
| Or prophylaxis | If urgent therapy is indicated in a patient not up to date, prescribe antibacterial drug prophylaxis and vaccinate as soon as possible. Optimal regimens and durations are not established; weigh the risks of prophylaxis against meningococcal risk. | FDA label |
| Baseline labs | Obtain lipase and amylase before initiating. | FDA label |
| Counsel and hand over materials | Counsel with the Patient Safety Card and Patient Guide, give copies, and tell the patient to carry the card at all times during treatment and for 2 months after the last dose. | FDA REMS page |
| Submit the Start Form | Fax to 1-833-FAX-UCB1 (1-833-329-8221), email ucbonward@rxallcare.com, or enroll online at ONWARDhcp-enroll-ZILBRYSQ.com. Attach clinical notes, the anti-AChR and/or anti-MuSK report, MGFA class, MG-ADL and the medication list. The prescription needs weight in kg with the date measured; quantity is 28 prefilled syringes. Wet signature only, no stamps. | Start Form |
| Vaccination page: hold or dispense | Page 4 records MenACWY, MenB or MenABCWY brands and dates, takes vaccine prescriptions that PANTHERx Rare can coordinate at retail or in-home with patient opt-in, and requires a choice: HOLD SHIPMENT for missing vaccines, or DISPENSE with an attestation and the urgent-start prophylaxis plan. | Start Form |
| Single specialty pharmacy | Prescriptions are filled only through PANTHERx Rare: phone 833-418-7760, fax 412-567-6135, or eRx. The March 2025 flashcard gives NPI 1659762524 for eRx; the September 2026 Start Form gives NPI 1750843314. Confirm with PANTHERx before e-prescribing. | Pharmacy flashcard |
| Expect the pharmacy's REMS calls | Before the first dispense, the pharmacy verifies prescriber certification and contacts the prescriber to document vaccination status or prophylaxis. For patients not up to date at the start, it repeats the check before each dispense for up to 6 months. | FDA REMS page |
| Benefits and PA | PANTHERx Rare runs the benefits investigation, starts PA with the office, and returns PA forms to the office for an appeal after a denial. It calls the patient for the cost share and to schedule shipment. | ONWARD insurance steps |
| Copay and PAP | Copay assistance to as little as $0 for commercial insurance; not valid with Medicare Part D or Medigap, employer plans for Medicare-eligible retirees, Medicaid, state pharmaceutical assistance, TRICARE, VA or DoD. The Patient Assistance Program may provide drug at no cost for up to 12 months on financial criteria. | Cost and copay terms |
Prior authorization criteria and what to document
One public policy as the example: Cigna, May 1, 2026. Approval six months at first, then 1 year at a time if the prescriber says you are still benefiting. This policy took effect in May 2026, before the October 2026 label added the autoinjector, and it cites the February 2025 label. The October change did not alter the dose or who Zilbrysq is for. The policy does not list the vaccines or the REMS, which the pharmacy checks separately. It counts a month as 30 days, while a pack lasts 28 days. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | Anti-AChR antibody-positive generalized myasthenia gravis, age 18 or older | Antibody report with date [documentation required] | Cigna policy |
| Severity | MGFA class II to IV and MG-ADL total 6 or more | Class and dated MG-ADL score sheet | Cigna policy |
| Pyridostigmine | Received or currently receiving, or inadequate efficacy, contraindication or significant intolerance | Dose, dates and outcome | Cigna policy |
| Immunosuppressants | Two different agents for 1 year or more, or inadequate efficacy, contraindication or significant intolerance to 2; examples azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus, cyclophosphamide | Agents, doses, dates and outcomes | Cigna policy |
| Unresolved symptoms | Evidence such as difficulty swallowing or breathing, or functional disability ending physical activity (double vision, talking, mobility) | Current note describing symptoms | Cigna policy |
| Prescriber | Prescribed by or in consultation with a neurologist | Specialty on the request, or the consult note | Cigna policy |
| Not covered | Concomitant use with another complement inhibitor (eculizumab products, Ultomiris), an FcRn blocker (Imaavy, Rystiggo, Vyvgart, Vyvgart Hytrulo), a rituximab product or Uplizna | Stop dates for prior biologics | Cigna policy |
| Renewal | Initial approval 6 months, then 1 year if, according to the prescriber, the patient continues to derive benefit (fewer exacerbations; better speech, swallowing, mobility or respiratory function) | Note describing benefit since start | Cigna policy |
Zilbrysq dosing and titration
| When | Label | Source |
|---|---|---|
| Under 56kg | 16.6mg/0.416mL SC once daily | FDA label |
| 56kg to under 77kg | 23mg/0.574mL SC once daily | FDA label |
| 77kg and above | 32.4mg/0.81mL SC once daily | FDA label |
| Administration | Abdomen, thighs or back of the upper arms; upper outer arm by a caregiver only. Rotate sites; avoid tender, bruised, red, hard, scarred or striated skin. Warm refrigerated product 30 to 45 minutes; do not heat. Patients may self-inject after training. | FDA label |
| Presentations | Prefilled syringe, 29G ½ inch needle, 28 per pack as 4 cartons of 7 (NDC 50474-990-80, -991-80, -992-80). Prefilled autoinjector, 28 per pack (NDC 50474-993-85, -994-85, -995-85), approved October 15, 2026; PK comparable to the syringe. | FDA label |
| Refill cadence | One pack is a 28-day supply. Room temperature storage up to 30°C for a single period of up to 3 months; do not return to the refrigerator. | FDA label |
| Missed dose | Administer as soon as possible, then resume the regular time. No more than 1 dose per day. | FDA label |
| Pharmacology | Complement inhibition 97.5% by end of week 1 in Study 1; steady-state troughs by week 4; terminal half-life about 172 hours (7 to 8 days). | FDA label |
Monitoring the Zilbrysq label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Before day 1 | Lipase and amylase; meningococcal vaccination status; unresolved serious meningococcal infection | Required by the label; initiation contraindicated with unresolved serious N. meningitidis infection | FDA label |
| Any time | Meningococcal infection: fever, fever with rash or tachycardia, headache with fever, nausea or vomiting, stiff neck or back, confusion, flu-like myalgia, photophobia | Evaluate immediately; treat promptly; consider interrupting Zilbrysq during treatment of serious meningococcal infection | FDA label |
| Any time | Other encapsulated bacterial infections: S. pneumoniae, H. influenzae, Neisseria species including disseminated gonococcal infection | Pneumococcal vaccination per ACIP; counsel on gonorrhea prevention and regular testing for those at risk; caution with any systemic infection | FDA label |
| Any time | Persistent abdominal pain, possibly radiating to the back, with or without vomiting | Discontinue if pancreatitis suspected until ruled out or resolved. Study 1: lipase up 6.9% against 0%, amylase 4.7% against 1.1%; extension studies: pancreatitis 1.9%, cysts 1.4% | FDA label |
| Per ACIP | Meningococcal boosters | Revaccinate considering the duration of therapy | FDA label |
| First 12 weeks | Injection site reactions 29% against 16%, URTI 14% against 7%, diarrhea 11% against 2%, UTI 8% against 5%; transient eosinophil rises of uncertain significance | Study 1, 86 on Zilbrysq and 88 on placebo | FDA label |
| Long term | Morphea in 10 of 213 (5%) in open-label extensions, mostly after more than 1 year, mild to moderate; 1 discontinuation | Skin exam at follow-up | FDA label |
Zilbrysq drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Drug interactions | No clinical interaction studies. Not a substrate of major CYP enzymes or of P-gp, BCRP, OATP1B1 or OATP1B3 in vitro; clinically relevant CYP, UGT and transporter interactions unlikely | FDA label |
| Renal impairment | No dose adjustment; exposure fell 13% in severe impairment | FDA label |
| Hepatic impairment | No adjustment in mild or moderate impairment; severe impairment not studied | FDA label |
| Pregnancy | No human data; embryofetal death in monkeys at exposures similar to the maximum human dose; registry via UCBCares 1-844-599-2273 or ucbcares@ucb.com | FDA label |
| Lactation and pediatrics | No lactation data; safety and effectiveness not established in pediatric patients | FDA label |
| Contraindicated | Initiation in patients with unresolved serious Neisseria meningitidis infection | FDA label |
Why a first fill stalls, and the fix
- The pharmacy cannot document your vaccinesThe REMS requires the pharmacy to check your vaccination status with the prescriber before the first shipment. If you were not up to date at the start, it keeps checking before each shipment for up to 6 months. The fix is the office sending vaccine dates or the antibiotic plan.
- The shipment is on hold for vaccinesOn the Start Form's vaccine page, the neurologist chooses either to hold the shipment until missing vaccines are given or to dispense. A hold is a choice the office made, so ask them which box was checked.
- The prescription went to another pharmacyUCB says prescriptions are filled only through PANTHERx Rare, which takes calls at 833-418-7760. The office resends it there, so this is a routing problem, not a denial.
- Prior authorization pending or deniedPlans ask for criteria like those in the Cigna policy below, such as a positive AChR antibody test and earlier medicines. If a plan denies coverage, UCB says PANTHERx Rare works with your neurologist on an appeal, and you do not need to act.
- You are also on another myasthenia antibody or complement drugThe Cigna policy below does not cover Zilbrysq taken alongside another complement inhibitor, an FcRn blocker such as Vyvgart or Rystiggo, rituximab or Uplizna. Ask the neurologist how a switch from another of these drugs is planned.
- A copay you cannot payCommercial insurance may bring the cost to as little as $0. The program's terms exclude Medicare, Medicaid, TRICARE, VA and other government plans. UCB's Patient Assistance Program may supply Zilbrysq at no cost for up to 12 months to people who qualify financially. Our help paying page lists charity funds that may help.
ONWARD
- A dedicated, medically trained Care Coordinator who calls after enrollment and helps with insurance and financial options
- Copay help for commercial insurance, as little as $0, not valid under Medicare, Medicaid, TRICARE, VA, DoD or other government plans Cost and copay terms
- The Patient Assistance Program, Zilbrysq at no cost for up to 12 months for people who meet its financial criteria Cost and copay terms
- Help getting the required vaccines through PANTHERx Rare, at a local pharmacy or at home, with a prescription from your neurologist Vaccination requirements
- A Welcome Kit with the first shipment and refresher injection coaching ONWARD treatment prep
- Symptom tracking tools and self-injection tips
Questions prescribers' offices ask about Zilbrysq
What is the Zilbrysq dose?
One SC injection daily by actual body weight, per the October 2026 label: 16.6mg under 56kg, 23mg from 56kg to under 77kg, and 32.4mg at 77kg or more. Inject the full contents of the single-dose prefilled syringe or autoinjector at about the same time each day; never more than 1 dose a day.
Which vaccines are required before Zilbrysq?
Meningococcal serogroups A, C, W, Y and B, completed or updated at least 2 weeks before the first dose on the ACIP schedule for complement inhibitor recipients, per the boxed warning and section 2.1 of the October 2026 label. Section 5.3 adds pneumococcal vaccination per ACIP. Revaccinate per ACIP for the duration of therapy.
Can Zilbrysq start before the vaccines have had 2 weeks?
Yes, if urgent therapy is indicated: sections 2.1 and 5.1 of the October 2026 label say to give antibacterial drug prophylaxis and administer the vaccines as soon as possible. It states that optimal prophylaxis regimens and durations have not been studied, and the REMS requires the prescriber to write the antibiotic prescription.
What does the Zilbrysq REMS require?
Prescriber enrollment before prescribing, per section 5.2 of the October 2026 label, plus counseling with the Patient Guide and Patient Safety Card, vaccination assessment, and a prophylaxis prescription for urgent starts. The certified pharmacy verifies prescriber certification and contacts the office about vaccination status before the first dispense, and before each dispense for up to 6 months if the patient was not up to date. REMS line 1-877-414-8353.
What do insurers ask for to approve Zilbrysq?
The Cigna policy shown on this page, effective May 1, 2026 and citing the February 2025 label, asks for age 18 or older, documented anti-AChR positivity, MGFA II to IV, MG-ADL of 6 or more, pyridostigmine, 2 immunosuppressants for a year or failure of them, unresolved symptoms and a neurologist. It approves 6 months, then 1 year on continued benefit, and excludes combination with another complement inhibitor, FcRn blocker, rituximab or Uplizna.
Free email alert
Get an email when the Zilbrysq label changes
One email the day the FDA revises the Zilbrysq prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Zilbrysq only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- ZILBRYSQ (zilucoplan) injection, for subcutaneous use, prescribing information, Medication Guide and Instructions for Use, revised October 2026, UCB, via Drugs@FDA, 2026-10-15.
- Approved Risk Evaluation and Mitigation Strategies (REMS), Zilbrysq (zilucoplan) NDA 216834, FDA, 2025-02-28.
- ZILBRYSQ REMS Patient Guide, what you need to know about ZILBRYSQ, UCB, via FDA REMS@FDA, 2025-02-28.
- ZILBRYSQ REMS Prescriber Enrollment Form, UCB, via FDA REMS@FDA, 2025-02-28.
- ONWARD and You (ZILBRYSQ) | UCB ONWARD, UCB, 2026-11-07.
- Insurance and ZILBRYSQ | UCB ONWARD, UCB, 2026-11-07.
- Treatment Prep | UCB ONWARD, UCB, 2026-11-07.
- Financial Support for ZILBRYSQ (zilucoplan) Injection, with the Copay Assistance Program terms and conditions, UCB, 2026-11-07.
- Vaccination Requirements for ZILBRYSQ, UCB, 2026-11-07.
- Start Form for ZILBRYSQ (zilucoplan) Injection For Subcutaneous Use, US-ZL-2600316, UCB, 2026-09-29.
- ZILBRYSQ (zilucoplan) Is Available Exclusively Through a Single Specialty Pharmacy, PANTHERx Rare, US-ZL-2500139, UCB, 2025-03-01.
- Drug Coverage Policy IP0622, Complement Inhibitors, Zilbrysq, Cigna, 2026-05-01.
- UCB announces U.S. FDA approval for ZILBRYSQ (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis, UCB, 2026-10-16.
- NDA 216834/S-015 approval letter, single-dose prefilled autoinjector, FDA, 2026-10-15.
- NDA 216834/S-013 approval letter, pregnancy exposure information contact, FDA, 2026-01-22.
- NDA 216834/S-008 and S-009 approval letter, meningococcal infection labeling and REMS modification, FDA, 2025-02-28.
- NDA 216834/S-001 approval letter, morphea added to postmarketing experience, FDA, 2024-04-26.
A reference drawn from the October 15, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 7, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.